Research programme: coronary restenosis therapy - SIDR
Alternative Names: Coronary restenosis therapy research programme - SIDR; Coronary restenosis therapy research programme - Strathclyde Institute for Drug Research; Research programme: coronary restenosis therapy - Strathclyde Institute for Drug Research; Research programme: restenosis therapy - Strathclyde Institute for Drug Research; Restenosis therapy research programme - SIDR; Restenosis therapy research programme - Strathclyde Institute for Drug ResearchLatest Information Update: 05 Feb 2008
Price :
$50 *
At a glance
- Originator Strathclyde Institute for Drug Research
- Class
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coronary artery restenosis
Most Recent Events
- 05 Feb 2008 No development reported - Preclinical for Coronary artery restenosis in United Kingdom (unspecified route)
- 13 Mar 2000 This programme is available for licensing (http://www.sidr.org)
- 20 Jul 1999 New profile